VIREAD Drug Patent Profile
✉ Email this page to a colleague
When do Viread patents expire, and when can generic versions of Viread launch?
Viread is a drug marketed by Gilead Sciences Inc and is included in two NDAs.
The generic ingredient in VIREAD is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Viread
A generic version of VIREAD was approved as tenofovir disoproxil fumarate by TEVA PHARMS USA on March 18th, 2015.
Summary for VIREAD
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 89 |
Clinical Trials: | 91 |
Patent Applications: | 4,317 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VIREAD |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIREAD |
What excipients (inactive ingredients) are in VIREAD? | VIREAD excipients list |
DailyMed Link: | VIREAD at DailyMed |
Recent Clinical Trials for VIREAD
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Université Protestant au Congo | Phase 4 |
Doris Duke Charitable Foundation | Phase 4 |
Albert Einstein College of Medicine | Phase 4 |
Pharmacology for VIREAD
Anatomical Therapeutic Chemical (ATC) Classes for VIREAD
Paragraph IV (Patent) Challenges for VIREAD
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VIREAD | Tablets | tenofovir disoproxil fumarate | 150 mg, 200 mg, and 250 mg | 021356 | 1 | 2012-05-17 |
VIREAD | Tablets | tenofovir disoproxil fumarate | 300 mg | 021356 | 1 | 2010-01-26 |
US Patents and Regulatory Information for VIREAD
Expired US Patents for VIREAD
International Patents for VIREAD
See the table below for patents covering VIREAD around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 1243590 | ⤷ Try a Trial | |
Portugal | 1243590 | ⤷ Try a Trial | |
Czech Republic | 9500272 | ⤷ Try a Trial | |
Slovenia | 1243590 | ⤷ Try a Trial | |
Japan | 3561272 | ⤷ Try a Trial | |
Greece | 3030754 | ⤷ Try a Trial | |
Australia | 756793 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIREAD
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1301519 | CR 2016 00012 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
1632232 | 132016000129226 | Italy | ⤷ Try a Trial | PRODUCT NAME: ASSOCIAZIONE DI RILPIVIRINA CLORIDRATO O UNA SUA FORMA TERAPEUTICAMENTE EQUIVALENTE PROTETTA DAL BREVETTO DI BASE, EMTRICITABINA E TENOFOVIR ALAFENAMIDE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE IL TENOFOVIR ALAFENAMIDE EMIFUMARATO(ODEFSEY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1112, 20160623 |
1663240 | PA2015037,C1663240-2 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: RILPIVIRINO ARBA TERAPINIU POZIURIU PRIIMTINOS JO FORMOS, TOKIOS KAIP RILPIVIRINO DRUSKOS,ISKAITANT RILPIVIRINO HIDROCHLORIDA, TENOFOVIRO, YPAC TENOFOVIRO DIZOPROKSILIO FUMARATO, IR EMTRICITABINODERINYS; REGISTRATION NO/DATE: EU/1/11/737/001 2011-11-28, EU/1/11/737/002 20111128 |
2924034 | 132019000000062 | Italy | ⤷ Try a Trial | PRODUCT NAME: DORAVIRINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE IN COMBINAZIONE CON LAMIVUDINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE IN COMBINAZIONE CON TENOFOVIR O UN SUO ESTERE, IN PARTICOLARE UN ESTERE DI DISOPROXIL O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE UN SALE FUMARATO(DELSTRIGO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1333/001-002, 20181127 |
1663240 | 375 5032-2016 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: RILPIVIRIN VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/EMTRICITABIN/TENOFOVIR-ALAFENAMID VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/16/1112 20160623 |
1632232 | CA 2016 00066 | Denmark | ⤷ Try a Trial | PRODUCT NAME: EN KOMBINATION AF: RILPIVIRINHYDROCHLORID ELLER EN TERAPEUTISK AEKVIVALENT FORM DERAF SOM ER BESKYTTET AF GRUNDPATENTET, EMTRICITABIN OG TENOFOVIRALAFENAMID, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623 |
2924034 | PA2019507 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: DORAVIRINAS ARBA JO DRUSKA, LAMIVUDINAS ARBA JO DRUSKA, TENOFOVIRAS ARBA JO ESTERIS, YPAC DIZOPROKSILO ESTERIS ARBA JO DRUSKA, YPAC FUMARATO DRUSKA; REGISTRATION NO/DATE: EU/1/18/1333 20181122 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |